Pegylated recombinant uricase(Chongqing Paijin Biotechnology Co Ltd)

Primary objectives: 1) To evaluate the safety and tolerability of HZBio1 after multiple administration in gout subjects; 2) To evaluate the pharmacokinetic (PK) characteristics of HZBio1 after multiple administration in gout subjects. Secondary objectives: 1) To preliminarily evaluate the pharmacodynamic (PD) characteristics of HZBio1 after multiple administration in gout subjects; 2) To preliminarily evaluate the immunogenicity of HZBio1 after multiple administration in gout subjects.